Connected Medical Device IP Protection

Connected Medical Device IP Protection describes the strategic protection of medical devices that no longer function as isolated physical products, but as part of connected digital health environments. These devices may include embedded software, sensors, cloud connectivity, mobile applications, remote monitoring functions, data analytics, cybersecurity layers, user interfaces, and interoperability features.

The term is useful because modern medical technology increasingly creates value through interaction. A connected insulin pump, a cardiac implant with remote monitoring, a surgical robot with data feedback, or a wearable diagnostic device may all contain protectable technical inventions. But the commercially relevant advantage often lies in how hardware, software, data, workflow integration, and clinical usability work together.

For IP management, this changes the question from “How do we protect a device?” to “How do we protect a connected medical solution?” That broader view is essential, because competitors may not copy the physical product directly. They may copy the data layer, the patient interface, the connectivity logic, the update model, the clinical workflow, or the ecosystem position around the product.

From physical device protection to connected system protection

Traditional medical device IP protection often began with the tangible product. The main focus was the mechanical structure, the sensor architecture, the device housing, the manufacturing process, the sterile interface, or the technical feature that made diagnosis or therapy possible.

That perspective still matters. Many connected medical devices depend on highly sophisticated physical components, and those components may be central to technical differentiation. A sensor that measures more accurately, a catheter that can be navigated more safely, or an implant that reduces energy consumption may remain classic patent territory.

But connected medical devices add a second layer. The device communicates, receives updates, exchanges data, interacts with users, and often becomes part of a wider treatment pathway. That means the protectable subject matter may sit across the entire system, not only inside the device casing.

A narrow protection strategy can therefore miss the real control points. If the physical product is protected but the remote monitoring workflow, data interpretation logic, or interoperability interface remains exposed, the company may still lose the strategic advantage that makes the device valuable in the market.

Why connectivity changes the meaning of medical device IP

Connectivity changes the commercial function of a medical device. The product may no longer be sold only as a piece of equipment, but as a service, platform, data source, patient engagement tool, or clinical decision-support environment.

This makes IP protection more dynamic. The same device can generate value through hardware performance, software functionality, validated data models, integration into hospital systems, or the ability to support reimbursement and regulatory evidence. The result is a layered protection problem. Patents, trade secrets, copyright, database protection, design rights, trademarks, contracts, technical standards, and regulatory exclusivities may all contribute to the overall protection architecture.

The role of software, data, and cloud infrastructure

In connected medical devices, software often determines what the device actually does in practice. It may control measurements, filter signals, detect anomalies, communicate with a mobile application, or support clinical interpretation.

Data is equally important. The device may generate patient data, performance data, usage data, calibration data, training data, or evidence for clinical improvement. Not all data is protectable as IP in the same way, but data access, data quality, data models, and data governance can become major competitive assets.

Cloud infrastructure adds another layer. Many connected devices rely on cloud processing, dashboards, remote maintenance, cybersecurity monitoring, and update distribution. The IP question then includes not only what is embedded in the device, but also what happens outside the device in the connected health environment.

Connected medical devices as ecosystem products

Connected medical devices often create value only when they fit into an ecosystem. They may connect patients, clinicians, hospitals, payers, manufacturers, service providers, regulators, and software partners.

This ecosystem character makes IP protection more relational. It is not only about stopping copying. It is also about controlling interfaces, managing collaboration, structuring access rights, defining licensing models, and ensuring that partners cannot appropriate the most valuable parts of the solution.

The ecosystem may include app stores, hospital information systems, electronic health records, cloud service providers, AI vendors, cybersecurity providers, and reimbursement platforms. Each connection can create both value and dependency.

For this reason, Connected Medical Device IP Protection must be understood as an IP management discipline. It protects technical invention, but it also protects the company’s position in a network of clinical, technical, regulatory, and commercial relationships.

What makes the term different from SaMD or Digital Health IP

Software as a Medical Device focuses on software that performs a medical function without being part of a hardware medical device. Connected Medical Device IP Protection is broader in a different direction. It includes devices where hardware, software, connectivity, and clinical workflow interact.

Digital Health IP is also broader. It may include wellness apps, telemedicine platforms, AI diagnostics, hospital software, digital therapeutics, or health data tools. Connected Medical Device IP Protection focuses more specifically on device-based digital health systems.

The distinction matters because a connected device has particular IP challenges. The hardware may be regulated, the software may be updated, the data may be sensitive, the interface may need interoperability, and the clinical performance may depend on the entire system.

In practice, the boundaries overlap. A connected medical device may include SaMD components, digital health services, AI tools, and platform features. The value of the term lies in bringing these elements together under one strategic protection concept.

A practical working definition

A practical definition is this: Connected Medical Device IP Protection is the structured protection of inventions, software, data-related assets, interfaces, designs, brands, know-how, and contractual positions that make a connected medical device clinically useful and commercially defensible.

This definition deliberately includes technical and non-technical protection layers. Connected medical devices rarely rely on one IP right alone. Their defensibility often comes from the combination of patents, secrecy, software protection, data governance, standards strategy, regulatory evidence, and market trust.

It also includes the word “commercially.” A protection strategy that looks legally complete may still fail if it does not protect the real value path. The important question is not only whether something can be protected, but whether the protection supports the way the device wins adoption, reimbursement, clinical confidence, and ecosystem access.

That is why this glossary term belongs in IP management. It is not a narrow legal label. It is a strategic lens for understanding how connected medical devices create, capture, and defend value in digital healthcare.

IP protection is important for connected medical devices because their value is often distributed across many layers. The device may contain a patented sensor, but the decisive advantage may also depend on software, data interpretation, remote monitoring, clinical workflow integration, cybersecurity, or patient engagement.

This makes connected medical devices particularly vulnerable to partial imitation. A competitor may avoid the protected hardware feature but reproduce the user experience, imitate the connectivity model, build around the data workflow, or capture the same clinical decision point with a different technical architecture.

Strong IP management helps companies identify what must be protected, what must be kept secret, what must be contractually controlled, and what must remain open enough for adoption. The goal is not maximum exclusivity everywhere. The goal is a protection architecture that supports clinical trust, market access, and sustainable differentiation.

Protecting the real source of clinical and commercial value

In connected medical devices, value does not always sit where it first appears. A device may look like a physical product, but the reason clinicians adopt it may be the workflow, the predictive function, the remote dashboard, or the way it reduces uncertainty in patient management.

That means the IP strategy must begin with value mapping. Companies need to ask which technical and informational elements make the solution better, safer, faster, easier, more reliable, or more economically attractive.

Only then can protection be aligned with the business model. If the business depends on recurring data services, protecting only the device hardware may be insufficient. If the device wins because it integrates smoothly into hospital systems, interface and interoperability strategy may be central.

If the value lies in clinical confidence, the protection strategy may also need to preserve the evidence base. Know-how, validated workflows, training data, quality processes, and regulatory documentation can all support defensibility, even when they are not protected in the same way as a patent.

Preventing competitors from copying around the device

Connected medical devices create many possible routes for design-around. A competitor may use different hardware but deliver a similar remote monitoring result. Another may create a software layer that sits between the device and the clinician, reducing the original manufacturer’s relevance.

This is why claims and protection layers must be drafted with the system in mind. Patent protection may need to cover interactions between device, software, server, user interface, and clinical workflow where legally possible.

The strategy should also anticipate substitution. If the same clinical problem can be solved through a different sensor, algorithm, data flow, or service model, the IP portfolio must protect the broader logic of value creation, not only one embodiment.

Securing investment, partnerships, and market access

Connected medical devices often require significant investment before they reach scale. Development may involve regulated engineering, clinical validation, cybersecurity testing, software maintenance, data infrastructure, and market access work.

Investors and partners need confidence that the company can protect the value created by that investment. A clear IP position can support fundraising, licensing, strategic collaborations, reimbursement discussions, and acquisition value.

In partnerships, IP protection also clarifies ownership and control. When device manufacturers collaborate with hospitals, software vendors, AI providers, cloud platforms, or research institutions, the risk of blurred ownership increases. A strong IP strategy helps prevent later disputes over inventions, data-derived insights, improvements, and platform extensions.

Supporting regulatory and clinical trust

Medical device markets are trust-driven. Regulators, clinicians, hospitals, and patients need confidence that a connected device is safe, reliable, secure, and clinically meaningful.

IP does not replace regulation. But IP management can support trust by protecting validated technical solutions, cybersecurity methods, quality processes, user interface designs, and clinical workflows that make the device dependable.

A company that controls its core technology can also manage updates, service continuity, and post-market improvements more effectively. This is especially important where connected devices remain active after deployment and evolve through software updates.

There is also a defensive dimension. If a company depends too heavily on third-party technologies without clear rights, continuity risks may arise. In healthcare, such risks can quickly become operational, regulatory, and reputational problems.

Capturing value beyond the first device sale

Connected medical devices often generate value after the initial sale. They may support subscription models, remote monitoring services, software updates, analytics, maintenance, training, or performance-based healthcare models.

This changes the IP logic. The company is not only protecting a product at the point of sale. It is protecting an ongoing relationship with users, data flows, clinical processes, and service infrastructure.

IP protection should therefore cover the parts of the solution that sustain recurring value. This may include software architecture, algorithms, user interfaces, data models, brand trust, service know-how, and contractual access to device-generated information.

A device manufacturer that ignores this layer may create a strong product but lose the service economy around it. In connected healthcare, that can mean losing the most scalable and strategically important part of the business.

Managing dependency in digital health ecosystems

Connected medical devices depend on other systems. They may require operating systems, communication protocols, cloud services, hospital IT integration, app stores, cybersecurity tools, AI components, or electronic health record access.

Each dependency can create an IP and business risk. If a critical technology is licensed too narrowly, if open-source obligations are misunderstood, or if an interoperability standard changes, the device strategy may be affected.

This is why freedom-to-operate analysis must extend beyond the physical device. It should include software dependencies, data rights, APIs, standards, third-party models, cloud arrangements, and partner contributions.

Good IP management does not try to eliminate all dependency. That would be unrealistic. It makes dependencies visible, negotiable, and manageable before they become barriers to clinical use or market expansion.

Connected medical devices are usually protected by a combination of IP rights rather than by a single legal tool. Patents may protect technical inventions, copyright may protect software code and certain design elements, trade secrets may protect algorithms and know-how, and trademarks may protect the trusted identity of the solution.

Data-related assets and interfaces require particular care. Data itself is not always protected as property in a simple way, and interoperability may require openness in some areas. This makes strategic design of protection boundaries especially important.

The right question is not only “Which IP right applies?” It is also “Which layer of the connected device system does this right protect, and how does that support the business model?”

Patents for technical device and system inventions

Patents can protect technical inventions in connected medical devices where the legal requirements for patentability are met. This may include sensor arrangements, signal processing methods, control systems, energy management, device communication mechanisms, calibration procedures, safety functions, or technical cybersecurity measures.

In many jurisdictions, software-related inventions may be patentable when they produce a technical effect or solve a technical problem. For connected medical devices, this can be important because software often interacts with the physical device or clinical measurement process.

Patent strategy should be system-aware. Claims may need to reflect how the device, server, mobile application, and clinical user interact. A narrowly drafted claim covering only one device component may not capture the commercially relevant connected solution.

Companies should also consider different claim categories where available. Device claims, method claims, system claims, computer-implemented method claims, and use-related claims may each play a role in protecting different parts of the value chain.

Copyright for software, content, and user interface elements

Copyright can protect software code as a literary work, although it usually protects expression rather than the underlying technical idea. For connected medical devices, this can help protect source code, object code, documentation, graphical elements, and certain screen layouts.

Copyright is useful but limited. A competitor may write different code that performs a similar function, so copyright rarely substitutes for patent protection where the technical concept is the main value.

Nevertheless, copyright can be important in enforcement and contracting. It can support control over copied code, copied documentation, copied training materials, or copied user interface assets. It also matters in software development agreements, where ownership of code must be clearly assigned.

Trade secrets for algorithms, data models, and know-how

Trade secrets are often central to connected medical device IP protection. They may cover algorithms, training methods, calibration routines, manufacturing parameters, clinical workflow insights, performance data, cybersecurity procedures, and quality assurance know-how.

The attraction of trade secrecy is that it can protect information that may not be patentable or that should not be disclosed. This can be especially relevant for AI models, data processing pipelines, and operational know-how that would be difficult for competitors to discover from the product alone.

The weakness is that secrecy requires active management. Companies need access controls, confidentiality agreements, employee policies, partner restrictions, documentation practices, and technical security measures. Once a secret is disclosed without protection, it may be difficult or impossible to recover the lost exclusivity.

Designs and trademarks for trust, usability, and market recognition

Design rights may protect the appearance of device housings, user interfaces, icons, dashboards, wearables, packaging, or other visual elements where the legal requirements are met. In medical technology, visual design can be more than decoration. It can support usability, trust, patient adherence, and safe interaction.

Trademarks protect names, logos, signs, and brand identifiers. For connected medical devices, brand protection can be highly valuable because clinicians and patients must trust the solution. A recognizable brand can carry associations of safety, regulatory compliance, clinical validation, and service reliability.

Trade dress and product presentation may also matter in some markets. A device that becomes familiar in clinical practice may develop recognition through its shape, interface, color scheme, or service environment.

These rights do not usually protect the technical function itself. Their role is different. They protect the market identity and user-facing trust signals that help the connected device become recognizable and preferred.

Database, data access, and contractual protection

Data is one of the most difficult areas in connected medical device IP. Device-generated data may be medically sensitive, regulated, shared across stakeholders, and technically valuable. It may also be subject to privacy, health data, and contractual restrictions that are separate from IP law.

In some jurisdictions, database rights may protect substantial investment in obtaining, verifying, or presenting database contents. Copyright may protect original database structures. But neither route should be treated as a simple ownership answer for all device-generated data.

Contractual protection is therefore essential. Agreements should define who may access data, for what purpose, under which conditions, and whether aggregated, anonymized, derived, or performance data may be used for improvement, training, analytics, or commercial services.

This is not only a legal hygiene issue. Data access can determine who learns fastest, who improves the product, who builds evidence, and who controls the next generation of connected medical services.

Interfaces, standards, APIs, and interoperability rights

Interfaces are strategically sensitive in connected medical devices. A device may need to communicate with hospital systems, mobile apps, cloud services, electronic health records, diagnostic equipment, or patient platforms.

Some interface technologies may be protectable by patents, copyright, trade secrets, or technical documentation rights. At the same time, interoperability requirements, standards, procurement expectations, and regulatory considerations may limit how closed the interface can be. APIs require careful IP and contract design. Documentation, access terms, usage restrictions, certification models, and developer policies can shape who may connect to the device ecosystem and under which conditions.

The strategic challenge is to decide what should be open, controlled, licensed, standardized, or kept proprietary. Excessive closure may slow adoption. Excessive openness may allow others to capture the most valuable ecosystem position.

Companies should build an IP strategy for connected medical devices by starting from the clinical and commercial value logic of the solution. The protection strategy should not be an afterthought that merely records inventions after development. It should help shape how the device, software, data, services, and ecosystem relationships become defensible.

A good strategy identifies the control points that matter most. These may be technical features, data flows, integration points, service processes, clinical evidence, safety functions, update mechanisms, or user trust signals.

Because connected medical devices evolve over time, the IP strategy must also be iterative. Software updates, new indications, new data uses, new partners, and new regulatory expectations can all change what needs to be protected.

Start with the connected value chain

The first step is to map the connected value chain. This means identifying how the device creates value from sensing, processing, communication, interpretation, clinical use, user interaction, maintenance, and post-market learning.

This mapping should include the patient, clinician, hospital, payer, manufacturer, service provider, software vendor, and data environment. A connected medical device often becomes valuable because these actors interact more effectively.

Once the value chain is visible, the company can identify where IP protection can create leverage. Some layers may need exclusivity. Others may need controlled access. Others may need openness to encourage adoption.

Without this mapping, IP protection can become too product-centered. The company may protect the visible device but fail to protect the system relationships that make the device difficult to replace.

Identify technical control points early

Technical control points are features that competitors would need in order to offer a comparable solution. In connected medical devices, they may include sensing accuracy, data compression, secure communication, battery management, calibration, alert logic, remote update mechanisms, or clinical decision-support functionality.

These control points should be identified early, before public disclosure, partner presentations, regulatory filings, or product launches create risks for patentability or secrecy. Early identification also helps development teams think strategically. Engineers and clinicians can be encouraged to document not only what works, but why it creates a defensible advantage in clinical practice.

Choose what to patent and what to keep secret

Not every valuable asset should be patented. Patents require disclosure, have a limited term, and may be easier to design around if the invention is narrow. Trade secrets require secrecy, but they can last longer if properly managed.

A connected medical device company should decide which inventions benefit from patent protection and which assets are better kept confidential. Hardware structures, technical communication methods, or measurable device functions may often be candidates for patents. Internal data processing methods, model training practices, and operational know-how may sometimes be better protected as trade secrets.

The decision should depend on detectability, reverse engineering risk, disclosure value, enforcement potential, regulatory transparency, and business relevance. A feature that competitors can easily observe may be difficult to protect by secrecy alone. A process hidden in the cloud may be more suitable for confidentiality.

Align IP strategy with regulatory and clinical milestones

Connected medical device development is shaped by regulatory milestones. Clinical evaluation, conformity assessment, software validation, cybersecurity documentation, risk management, and post-market surveillance can all affect the timing and content of disclosures.

IP strategy must therefore be synchronized with the regulatory pathway. Patent filings should be considered before enabling disclosures. Trade secret boundaries should be defined before documentation is shared widely. Contracts should clarify ownership before clinical collaborations begin.

Clinical evidence can also become a strategic asset. The way a company designs studies, collects performance data, and validates workflow benefits may support both regulatory approval and market differentiation. This does not mean that regulatory documents are IP rights. It means that regulatory and clinical work can reveal or strengthen the protected value of the connected device, and the IP strategy should anticipate that interaction.

Build contractual architecture around partnerships

Connected medical devices are rarely developed alone. Companies may work with software developers, hospitals, CROs, universities, cloud providers, AI vendors, cybersecurity specialists, design agencies, distributors, and manufacturing partners.

Each collaboration should be supported by clear contractual architecture. Agreements should define background IP, foreground IP, improvements, data rights, confidentiality, publication rights, sublicensing, regulatory responsibilities, and exit scenarios.

This is especially important where partners contribute to software, data models, interfaces, or clinical validation. Without clear ownership and usage rights, the company may later discover that it cannot freely commercialize or improve its own connected device system. Contracts should also reflect the difference between contribution and control. A partner may provide a component, but that should not automatically give the partner influence over the broader device ecosystem unless intended.

Plan for updates, versions, and lifecycle protection

Connected medical devices do not remain static. Software updates, cybersecurity patches, algorithm improvements, new indications, user interface changes, and integration features may be introduced throughout the lifecycle.

IP strategy should therefore include a lifecycle process. Each update should be assessed for potential patentable inventions, trade secret value, copyright ownership, regulatory implications, open-source issues, and contractual constraints. Version control is important. The company should know which rights apply to which software version, device generation, clinical dataset, interface specification, or service model.

Lifecycle protection also supports enforcement and licensing. If the company cannot show how its protected assets evolved, it may struggle to prove ownership, scope, or strategic relevance when disputes or transactions arise.

Connect IP protection to business model design

The business model determines which IP assets matter most. A company selling devices may need different protection than a company offering remote monitoring subscriptions, data analytics, software-enabled services, or platform access.

If revenue comes from hardware margins, patents on device architecture may be central. If revenue comes from recurring services, software, data access, brand trust, and contractual control may become more important.

If the strategy involves partnerships with hospitals or insurers, the IP position must support collaboration rather than block it. If the strategy involves platform leadership, interface governance and ecosystem access may become decisive.

A strong IP strategy does not simply protect what has already been built. It supports the company’s chosen route to value capture. In connected medical devices, that route is often as important as the device itself.

Connected medical devices create IP risks because they operate in shared technical environments. They exchange data, rely on interfaces, use third-party software, receive updates, and interact with healthcare infrastructure that may not be controlled by the device manufacturer.

These risks are not only legal. They can become operational, clinical, regulatory, and commercial. A missing software license, unclear data right, weak cybersecurity control, or problematic interface dependency may affect whether the device can be used safely and sustainably.

For this reason, IP risk management must be integrated into product development, regulatory planning, procurement, partnerships, and post-market operations.

Interoperability as both opportunity and exposure

Interoperability helps connected medical devices become useful. A device that integrates into hospital systems, electronic health records, clinical dashboards, and patient platforms can reduce friction and increase adoption.

But interoperability can also expose value. The more a device connects to other systems, the more it may reveal technical specifications, data structures, workflow logic, or commercially important integration points.

Companies must therefore decide which interfaces should be open and which should be controlled. Open interoperability can support market access, but uncontrolled access may allow competitors or platform partners to capture the user relationship.

This creates a strategic tension. Healthcare systems often need interoperability, while device manufacturers need defensibility. Good IP management does not deny this tension. It structures it through API terms, certification models, licensing, technical access controls, and clear documentation.

Cybersecurity and IP protection overlap

Cybersecurity is usually discussed as a safety and compliance issue, but it also has an IP dimension. Security architecture, threat detection, authentication, encryption implementation, secure update mechanisms, and resilience processes may contain protectable know-how or patentable technical features.

At the same time, weak cybersecurity can destroy IP value. If source code, algorithms, technical documentation, product roadmaps, or clinical datasets are exposed, the company may lose confidentiality and competitive advantage.

The overlap between cybersecurity and IP protection should therefore be managed deliberately. Access control, logging, segmentation, secure development practices, and supplier security obligations can all help preserve trade secrets and confidential technical assets.

Software updates and shifting protection boundaries

Software updates can improve safety, usability, cybersecurity, and clinical performance. They can also create new IP assets or modify the relevance of existing ones.

A feature introduced in an update may be patentable. A new algorithm may need trade secret protection. A new interface may require API terms. A new user interface may raise design or copyright questions.

Updates can also create compliance and ownership risks. If third-party code is added, open-source obligations may arise. If a contractor develops an update, ownership must be clear. If an update changes data processing, contractual and privacy implications may follow.

This makes update governance an IP issue. Companies should treat major updates as moments for IP review, not only as engineering releases.

Healthcare data ecosystems and access rights

Healthcare data ecosystems are complex because patients, clinicians, hospitals, payers, manufacturers, software providers, and regulators may all have legitimate interests in the same data environment.

IP law alone rarely answers who may use connected device data. Privacy law, medical confidentiality, contractual terms, procurement rules, cybersecurity requirements, and ethical expectations all shape what is possible.

For IP strategy, the key issue is often access to usable data. A company may need data to improve algorithms, validate performance, train models, detect failures, support reimbursement, or develop future services.

If data rights are unclear, the company may lose learning advantages. If rights are too aggressively claimed, trust and adoption may suffer. The solution is usually a carefully designed data governance model that distinguishes personal data, technical performance data, aggregated data, derived insights, and anonymized learning datasets.

Open source, third-party software, and platform dependency

Connected medical devices often use open-source software, third-party libraries, operating systems, cloud platforms, communication modules, and external development tools. These elements can accelerate development, but they can also create legal and operational dependencies.

Open-source licenses may impose obligations that affect distribution, disclosure, modification, or combination with proprietary code. Mismanagement can create serious problems, especially in regulated products that require long-term maintenance and traceability.

Third-party platform dependency is another risk. A device may rely on a cloud provider, mobile operating system, app store, AI model, cybersecurity vendor, or hospital integration platform. If access changes, costs rise, or licensing terms shift, the connected medical device business may be affected.

IP risk management should therefore include software bill of materials, license reviews, supplier audits, escrow options where appropriate, exit planning, and technical architecture choices that reduce critical lock-in.

Standards, essential patents, and access constraints

Connected medical devices often rely on communication standards, interoperability protocols, wireless technologies, cybersecurity frameworks, and healthcare data standards. Some standards may be associated with patents or licensing obligations.

Standard-essential patent issues can be relevant where devices use standardized communication technologies. Even where the medical function is unique, connectivity may depend on technologies developed in other industries.

Standards can also create strategic opportunities. A company with strong technology in safety-critical interfaces, data exchange, device authentication, or remote monitoring workflows may seek to influence standards or build licensed reference implementations.

The risk is that standards can both open and constrain markets. They can enable adoption, but they can also reduce differentiation if the company has not protected the layers above or around the standard. The strategic task is to know which layers should be standardized, which should be licensed, and which should remain proprietary.

Legal disclaimer

This glossary article is for general information and educational purposes only. It does not constitute legal advice, regulatory advice, medical device compliance advice, or a recommendation for any specific IP filing, licensing, enforcement, data governance, cybersecurity, or commercialization strategy.

Connected medical device IP protection depends on the applicable jurisdiction, the technical design of the device, the regulatory classification, the software architecture, the data flows, the contractual setup, and the commercial model. Companies should obtain advice from qualified IP, regulatory, data protection, cybersecurity, and medical device professionals before making decisions in a specific case.